Wynn Capital LLC Purchases Shares of 1,572 Danaher Co. (NYSE:DHR)

Wynn Capital LLC purchased a new stake in shares of Danaher Co. (NYSE:DHR) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 1,572 shares of the conglomerate’s stock, valued at approximately $364,000.

Several other institutional investors have also added to or reduced their stakes in DHR. Wellington Management Group LLP grew its holdings in Danaher by 18.6% during the 3rd quarter. Wellington Management Group LLP now owns 24,930,281 shares of the conglomerate’s stock valued at $6,185,203,000 after buying an additional 3,905,449 shares in the last quarter. Allen Investment Management LLC lifted its stake in shares of Danaher by 1,440.7% in the 3rd quarter. Allen Investment Management LLC now owns 1,100,399 shares of the conglomerate’s stock valued at $273,009,000 after purchasing an additional 1,028,976 shares during the last quarter. J.P. Morgan Private Wealth Advisors LLC bought a new stake in shares of Danaher in the 3rd quarter valued at approximately $178,850,000. Alecta Tjanstepension Omsesidigt bought a new stake in shares of Danaher in the 4th quarter valued at approximately $161,994,000. Finally, Harris Associates L P lifted its stake in shares of Danaher by 27.7% in the 3rd quarter. Harris Associates L P now owns 2,963,899 shares of the conglomerate’s stock valued at $735,343,000 after purchasing an additional 642,759 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Stock Down 1.1 %

Shares of NYSE:DHR traded down $2.70 on Wednesday, reaching $250.41. The company had a trading volume of 3,064,441 shares, compared to its average volume of 2,783,958. Danaher Co. has a 52-week low of $182.09 and a 52-week high of $259.00. The firm’s 50 day simple moving average is $248.95 and its 200-day simple moving average is $230.64. The firm has a market capitalization of $185.44 billion, a PE ratio of 39.12, a PEG ratio of 3.96 and a beta of 0.83. The company has a current ratio of 1.68, a quick ratio of 1.37 and a debt-to-equity ratio of 0.31.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. Danaher had a return on equity of 12.25% and a net margin of 17.26%. The business had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.62 billion. During the same period last year, the business posted $2.36 EPS. The business’s revenue was down 2.6% compared to the same quarter last year. As a group, analysts expect that Danaher Co. will post 7.62 earnings per share for the current fiscal year.

Danaher Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, April 26th. Stockholders of record on Thursday, March 28th will be issued a $0.27 dividend. The ex-dividend date is Wednesday, March 27th. This is an increase from Danaher’s previous quarterly dividend of $0.24. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.43%. Danaher’s dividend payout ratio (DPR) is currently 16.90%.

Analysts Set New Price Targets

A number of brokerages recently issued reports on DHR. StockNews.com lowered Danaher from a “buy” rating to a “hold” rating in a research note on Wednesday, January 31st. Bank of America raised their price target on Danaher from $258.00 to $270.00 and gave the stock a “neutral” rating in a research note on Wednesday. TD Cowen raised their price target on Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research note on Wednesday. KeyCorp raised their price target on Danaher from $260.00 to $290.00 and gave the stock an “overweight” rating in a research note on Thursday, February 1st. Finally, Barclays raised their price target on Danaher from $260.00 to $270.00 and gave the stock an “equal weight” rating in a research note on Wednesday. Six equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat, Danaher currently has a consensus rating of “Moderate Buy” and an average price target of $270.00.

Insider Buying and Selling

In related news, SVP Georgeann Couchara sold 2,622 shares of the business’s stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $242.67, for a total transaction of $636,280.74. Following the transaction, the senior vice president now directly owns 4,244 shares in the company, valued at approximately $1,029,891.48. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In other Danaher news, SVP Georgeann Couchara sold 2,622 shares of Danaher stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $242.67, for a total transaction of $636,280.74. Following the completion of the sale, the senior vice president now owns 4,244 shares of the company’s stock, valued at approximately $1,029,891.48. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Walter G. Lohr sold 3,289 shares of the company’s stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $251.15, for a total value of $826,032.35. Following the completion of the transaction, the director now directly owns 14,129 shares of the company’s stock, valued at approximately $3,548,498.35. The disclosure for this sale can be found here. Insiders have sold a total of 32,957 shares of company stock worth $8,265,802 in the last ninety days. 10.90% of the stock is owned by insiders.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.